Latest Breaking News On - Vissia viglietta - Page 1 : comparemela.com

How an Unproven Alzheimer’s Drug Got Approved Though some of its own senior officials said there was little evidence of benefit for patients, the F.D.A. nonetheless greenlighted Biogen’s Aduhelm, or aducanumab. The F.D.A. conducted an internal inquiry this year after allegations were made that the agency was collaborating too closely with Biogen, maker of the Alzheimer’s drug Aduhelm.Credit.Andrew Kelly/Reuters Published July 19, 2021Updated July 20, 2021, 9:29 a.m. ET Two months before the Food and Drug Administration’s deadline to decide whether to approve Biogen’s controversial Alzheimer’s drug, aducanumab, a council of senior agency officials resoundingly agreed that there wasn’t enough evidence it worked.

New yorkUnited statesSamantha budd haeberleinJanet woodcockRick pazdurBilly dunnVissia vigliettaPriya singhalWilliamb schultzMaria carrilloAl sandrockPatrizia cavazzoniMichael felberbaumBudd haeberleinWayne pinesNew york times